CVE-2016-8355
CADD-Solis Medication Safety Software grants an authenticated user elevated privileges on the SQL database, which would allow an authenticated user to modify drug libraries, add and delete users, and change user permissions.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.49%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
An issue was discovered in Smiths-Medical CADD-Solis Medication Safety Software, Version 1.0; 2.0; 3.0; and 3.1. CADD-Solis Medication Safety Software grants an authenticated user elevated privileges on the SQL database, which would allow an authenticated user to modify drug libraries, add and delete users, and change user permissions. According to Smiths-Medical, physical access to the pump is required to install drug library updates.
- CVSS 3.0
- 9.9 CRITICALCVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H
- EPSS
- 1.49% probability · 74th percentile
- Public exploits
- None in Exploit-DB
- CISA KEV
- Not listed
- Weakness
- CWE-306
- Affected
- smiths-medical/cadd-solis medication safety software
- Source
- ics-cert@hq.dhs.gov
EPSS 1.5% since 27 October 2026; no change recorded yet. Points are recorded when the score first appears and whenever it moves by a percentage point or more.
References
- http://www.securityfocus.com/bid/94630Third Party Advisory, VDB Entry
- https://ics-cert.us-cert.gov/advisories/ICSMA-16-306-01Third Party Advisory, US Government Resource
- http://www.securityfocus.com/bid/94630Third Party Advisory, VDB Entry
- https://ics-cert.us-cert.gov/advisories/ICSMA-16-306-01Third Party Advisory, US Government Resource
Source: NVD record, EPSS from FIRST.org, KEV from CISA, exploits from Exploit-DB. Refreshed daily. Download this record as JSON.